Bio-Techne Corporation (TECH)

In the past six months, Bio-Techne's stock has been influenced by its quarterly earnings reports and broader market conditions. In Q4 Fiscal 2025, Bio-Techne reported adjusted EPS of $0.53, with organic revenue increasing by 3% to $317.0 million and also announced the divestiture of its Exosome Diagnostics business. An Annual General Meeting was held on October 30, 2025. In Q1 Fiscal 2026, the company posted an EPS of $0.42, exceeding analysts' expectations by 5.00%. In Q2 Fiscal 2026, Bio-Techne reported adjusted EPS of $0.46, beating estimates by 8.2%, with revenue at $295.9 million. Over the past six months, Bio-Techne's stock has seen a gain of 33.91%, closing at $66.81 as of February 6, 2026.

While there isn't a clear indication of strict calendar-based demand seasonality for Bio-Techne's products and services, the company's revenue can be influenced by customer-specific headwinds and market conditions. Demand can fluctuate based on funding levels in research institutions and the timing of large orders from key customers, rather than predictable seasonal patterns. Bio-Techne anticipates a normalization in GMP reagent demand for its cell therapy business as these customer-specific headwinds abate and as comparisons reset in fiscal year 2027.

Bio-Techne Corp. is a global life sciences company focused on developing, manufacturing, and supplying reagents, analytical instruments, and diagnostics for the research, diagnostics, and bioprocessing markets. The company operates in the healthcare sector, specifically in life sciences tools and services. Bio-Techne's business is segmented into Protein Sciences and Diagnostics and Spatial Biology. The Protein Sciences segment focuses on biological reagents, while the Diagnostics and Spatial Biology segment provides diagnostic products and assays. The company's product portfolio includes over 24,000 products, with 95% manufactured in-house.

Bio-Techne has a global presence with offices in North America, Europe, and Asia. The United States accounts for approximately 55% of its revenue, with Europe, the Middle East, and Africa contributing 20%, the UK 5%, and Asia-Pacific 15%. The company has subsidiaries in various European countries and a significant presence in China and Hong Kong, including a wholly-owned subsidiary and distribution center in Shanghai.

Bio-Techne has maintained a positive brand reputation in the past year. The company was recognized in Forbes' "America's Dream Employers (2026)" and "America's Best Midsize Employers (2025)" in the Drugs & Biotechnology category. In 2026, Bio-Techne is celebrating its 50th anniversary, highlighting its long-standing presence and contributions to the life sciences industry. The company emphasizes its role in advancing science and medicine to improve lives worldwide.

Bio-Techne Corporation has a significant institutional ownership base, with 1189 institutional owners and shareholders holding a total of 196,442,678 shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Morgan Stanley. Insider trading activity in the past year has shown mixed signals, with some insider selling reported between August 2025 and February 2026.